Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVDX3 in Distal Radius Fractures
2023-508321-27-00Phase 2Completed
- Sponsor
- Novadip Biosciences
- Start
- Jan 2024
- Modality
- Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of NVD-X3 in distal forearm fracture, sponsored by Novadip Biosciences. Started Jan 2024; status: completed.
02
Drugs
NVD-X3
03
Conditions
distal forearm fracture
Beyond the preview
Go deeper on 2023-508321-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508321-27-00.